Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

How to Train Your Dragon's 3D/4DX ride excels in the movement category, but manages to fall short in most of the other categories measured.

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

The table below is a review of notable updates that occurred in May 2025 for investigational products in development (not an inclusive list). Click on the ...

ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer — Impressive PFS with combination of trastuzumab deruxtecan and pertuzumab ...

Her main takeaway was that while trastuzumab deruxtecan plus pertuzumab could be a new standard of care, questions remain—especially regarding optimal treatment sequencing and duration of therapy.

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...

Background: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) showing significant promise in treatment of metastatic HER2+ and HER2-low breast cancer. This systematic review and ...

Trastuzumab deruxtecan (T-DXd) monotherapy in advanced HER2-positive or HER2-low/ultralow breast cancer: An updated pooled analysis of prospective clinical trials.. If you have the appropriate ...